The Neonatal Drug Development Fund (NDDF) is a philanthropic research fund, created at the Floating Hospital for Children at Tufts Medical Center with the support of Therabron Therapeutics, Inc. The […]
- Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.
- Therabron Therapeutics to Present at Stifel 2016 Healthcare Conference
- Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
- Therabron Therapeutics to Present at Upcoming Industry and Investor Conferences
- Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants